# Dale Pfost

> Dale Pfost is a Series B investor at Advent Life Sciences backing Health Care and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Advent Life Sciences](https://shizune.co/investors/profile/advent-life)
- Location: San Francisco Bay Area, United States
- Total investments: 2
- Last investment: Mar 2015
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dale-pfost-00bb8/
- Facebook: https://www.facebook.com/dale.pfost

Dale Pfost is a Series B investor at Advent Life Sciences in San Francisco Bay Area focused on Health Care and Biotechnology. Dale Pfost joined Advent in 2010. He has more than 25 years of experience as a life science entrepreneur and executive, with expertise in high technology research tools, genomics, diagnostics and therapeutics. Dale's first company, founded while he was in graduate school, was acquired by SmithKline Beckman. He was founding CEO andChairman of Orchid BioSciences, a pioneer in genetic analysis and personalized medicine that Dale and his team built through strategic acquisitions and took public in 2000 (NASDAQ: ORCH). Dale then became founding CEO and Chairman of Acuity Pharmaceuticals, an innovative ophthalmology company that was acquired by OPKO Health (NYSE AMEX: OPK). As CEO of cancer drug developer Receptor BioLogix, Dale readied the company for a successful acquisition by a European biotechnology firm. Earlier in his career, he was co-founder and CEO of Advent-backed Oxford GlycoSciences (IPO on NASDAQ and LSE).

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Biotechnology | 1 | 50% |
| Manufacturing | 1 | 50% |
| Pharmaceutical | 1 | 50% |
| Information Technology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aura Biosciences | Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives ofpeople with a wide range of cancers that are poorly managed today.The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts. | $21M | Series B | Mar 05, 2015 |  |
| Vestagen Technical Textiles | Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in2009 and Based in Orlando, Florida. | $8.3M |  | Aug 27, 2013 |  |

2 of 2 investments shown.

## Co-investors
- [Lysosomal Therapeutics](https://shizune.co/investors/profile/lysosomal-therapeutics) — VC Fund, 1 deal together
- [Pappas Ventures](https://shizune.co/investors/profile/pappas-ventures) — VC Fund, 1 deal together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 1 deal together

## About Advent Life Sciences

VC Fund · London, United Kingdom

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

5 contacts available at Advent Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew J Wood | Venture Partner | https://shizune.co/investors/profile/andrew-j-wood |
| Dale Pfost | General Partner | https://shizune.co/investors/profile/dale-pfost |
| Kaasim Mahmood | General Partner | https://shizune.co/investors/profile/kaasim-mahmood |
| Satish Jindal | General Partner | https://shizune.co/investors/profile/satish-jindal |
| Shahzad Malik | General Partner | https://shizune.co/investors/profile/shahzad-malik |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Dale Pfost invest in?

Dale Pfost invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series B and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dale Pfost last invest?

The most recent investment recorded for Dale Pfost closed in Mar 2015. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co